Bank of Nova Scotia
FOLD

Bank of Nova Scotia’s Amicus Therapeutics FOLD Stock Holding History

Bank of Nova Scotia’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-193,050
Closed -$1.94M – 954
2017
Q2 		$1.94M Buy
+193,050
New +$1.55M 0.01% 636

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Bank of Nova Scotia's FOLD Position: Q3 2017 in Review

Bank of Nova Scotia sold out of Amicus Therapeutics (FOLD) in Q3 2017, closing a stake of 193,050 shares — an estimated $1.94M sold.

Bank of Nova Scotia first reported a position in FOLD in Q2 2017 and held it in 1 quarter. The position peaked at $1.94M in Q2 2017. 186 funds tracked by Wall St. Rank hold FOLD as of Q3 2017.

  • Bank of Nova Scotia reported no remaining Amicus Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Bank of Nova Scotia sold 193,050 Amicus Therapeutics shares in Q3 2017, an estimated $1.94M.
  • Bank of Nova Scotia first reported a position in Amicus Therapeutics in Q2 2017 and held it in 1 quarter.
  • Bank of Nova Scotia's Amicus Therapeutics position peaked at $1.94M in Q2 2017.
  • 186 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2017.

Based on Bank of Nova Scotia's 13F filing for Q3 2017, filed 14 Nov 2017.